Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May;142(6):1314-1323.e1.
doi: 10.1053/j.gastro.2012.02.013.

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus

A Sidney Barritt 4th  1 , Michael W Fried
Affiliations
Review

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus

A Sidney Barritt 4th et al. Gastroenterology. 2012 May.

Abstract

Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiviral (DAA) agents approved, and many more are being developed. These drugs substantially increased rates of sustained virologic response in treatment-naïve and -experienced patients, in conjunction with peginterferon and ribavirin (triple therapy), in phase 3 trials. The efficacy of triple therapy depends on appropriate selection of patients, although the population of patients that receive triple therapy could be expanded as the risk/benefit ratio improves. Attention to details that reflect the standard of care, such as appropriate dosing, anticipation of adverse effects, and strict adherence to stopping rules, will insure the success of these drugs and lead the way for new combination therapies.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors disclose the following: Dr Barritt receives research grants from Tibotec and has been on the Salix speaker’s bureau. Dr Fried receives research grants from Genentech, Vertex, Tibotec, Janssen, Gilead, Abbott, Bristol-Myers Squibb, and Anadys. He also serves as an ad hoc consultant to Genentech, Vertex, Merck, Tibotec, Janssen, Bristol-Myers Squibb, Novartis, and Gilead.

Figures

Figure 1
Figure 1
Duration for telaprevir and boceprevir-based triple therapy, based on previous treatment.
See this image and copyright information in PMC

References

    1. Steinkuhler C, Biasiol G, Brunetti M, et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry. 1998;37:8899–8905. - PubMed
    1. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem. 2005;280:36784–36791. - PubMed
    1. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother. 2005;49:4305–4314. - PMC - PubMed
    1. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767– 1777. - PubMed
    1. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850. - PubMed

Publication types

MeSH terms

Substances